Nxera Pharma Co., Ltd. (TYO:4565)
1,680.00
-65.00 (-3.72%)
Nov 18, 2026, 10:40 AM JST
Nxera Pharma Revenue
Nxera Pharma had revenue of 8.83B JPY in the quarter ending September 30, 2026, with 30.77% growth. This brings the company's total for the last twelve months to 35.51B, up 23.72% year-over-year. In the year 2025, Nxera Pharma had annual revenue of 29.62B with 2.71% growth. That makes Nxera Pharma the 16,750th largest company in the world by revenue and 1,821st in Japan.
Revenue (ttm)
35.51B
Revenue Growth
+23.72%
P/S Ratio
4.49
Revenue / Employee
113.09M
Employees
314
Market Cap
153.54B
Revenue by Geography
- Japan 17.97B 60.7%
- United States of America 4.89B 16.5%
- Switzerland 2.17B 7.3%
- United Kingdom 1.77B 6.0%
- Bermuda 1.41B 4.7%
- Germany 1.34B 4.5%
- Others 74.00M 0.2%
Fiscal year ended Dec 31, 2025 See the full Nxera Pharma breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 29.62B | 780.00M | 2.71% |
| Dec 31, 2024 | 28.84B | 16.07B | 125.87% |
| Dec 31, 2023 | 12.77B | -2.80B | -18.00% |
| Dec 31, 2022 | 15.57B | -2.14B | -12.10% |
| Dec 31, 2021 | 17.71B | 8.87B | 100.32% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| GNI Group | 37.21B |
| PeptiDream | 20.48B |
| 3-D Matrix | 11.92B |
| RaQualia Pharma | 3.90B |
| Heartseed | 3.03B |
| Japan Tissue Engineering | 2.68B |
| Cuorips | 72.00M |
| Healios K.K. | 47.00M |
Nxera Pharma News
- 1 day ago - Nxera Pharma Transcript: Jefferies Global Healthcare Conference - Transcripts
- 18 days ago - Nxera Pharma Earnings Call Transcript: Q3 2026 - Transcripts
- 18 days ago - Nxera Pharma Quarterly report: Q3 2026 - Filings
- 18 days ago - Nxera Pharma Slides: Q3 2026 - Filings
- 3 months ago - Nxera Pharma Earnings Call Transcript: Q2 2026 - Transcripts
- 3 months ago - Nxera Pharma Quarterly report: Q2 2026 - Filings
- 3 months ago - Nxera Pharma Slides: Q2 2026 - Filings
- 5 months ago - Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery - GlobeNewsWire